Curis, Inc.  

(Public, NASDAQ:CRIS)   Watch this stock  
Find more results for CRIS
2.54
-0.04 (-1.55%)
Mar 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.47 - 2.63
52 week 1.09 - 3.50
Open 2.58
Vol / Avg. 614,485.00/2.14M
Mkt cap 273.94M
P/E     -
Div/yield     -
EPS -0.22
Shares 103.18M
Beta 2.01
Inst. own 35%
May 21, 2015
Curis Inc Annual Shareholders Meeting (Estimated) - 10:00AM EDT - Add to calendar
May 6, 2015
Q1 2015 Curis Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 10, 2015
Curis Inc at ROTH Conference - Webcast
Mar 4, 2015
Curis Inc at Cowen Health Care Conference - Webcast
Feb 24, 2015
Q4 2014 Curis Inc Earnings Release
Feb 10, 2015
Curis Inc at Biotechnology Industry Organization CEO & Investor Conference
Jan 21, 2015
Curis Inc and Aurigene Announce Collaboration Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -285.49% -190.27%
Operating margin -241.44% -161.14%
EBITD margin - -159.57%
Return on average assets -34.88% -26.16%
Return on average equity -70.83% -49.97%
Employees 35 -
CDP Score - -

Address

4 Maguire Rd
LEXINGTON, MA 02421-3112
United States - Map
+1-617-5036500 (Phone)
+1-617-5036501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Curis, Inc. (Curis) is engaged in the research and development of innovative cancer therapeutics. The Company conducts its research and development programs both internally and through strategic collaborations. Its drug cancidate, Erivedge, which is approved medicine for the treatment of advanced basal cell carcinoma (BCC), is commercialized by F. Hoffmann-La Roche Ltd (Roche) and Genentech Inc., (Genentech), a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis�s development programs include both internal and under collaboration. The Company�s drug candidates include Dual histone deacetylas (HDAC) and phosphatidylinositol-3-kinase (PI3K) Inhibitor, which is CUDC-907; an antagonist of inhibitor of apoptosis (IAP) proteins, which is CUDC-427; Hedgehog Pathway Inhibitors, which include Erivedge, and HSP90 Inhibitor, which include Debio 0932.

Officers and directors

James R. McNab Jr. Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Ali Fattaey Ph.D. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Daniel R. Passeri J.D. Vice Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Michael P. Gray Chief Financial Officer
Age: 44
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jaye Viner M.D. Chief Medical Officer, Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Kenneth J. Pienta M.D. Director
Age: 53
Bio & Compensation  - Reuters
Martyn D. Greenacre Independent Director
Age: 72
Bio & Compensation  - Reuters
Kenneth I. Kaitin Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
Robert E. Martell M.D., Ph.D. Independent Director
Age: 51
Bio & Compensation  - Reuters
Marc Rubin M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters